Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunovion Pharmaceuticals Inc.

Division of Sumitomo Chemical Co.
www.sunovion.com

Latest From Sunovion Pharmaceuticals Inc.

Keeping Track: Turalio, Nubeqa And Accrufer Mark Trio Of Novel Drug Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Blonanserin On Course As First Atypical For Adolescent Schizophrenia In Japan

Dainippon drug likely to become first atypical to be approved for adolescent schizophrenia in Japan following planned filing based on positive new Phase III results.

Japan Clinical Trials

Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

US FDA Converges With Other Regulators On Insomnia Drug Warnings, But Broader Safety Disagreements Persist

US FDA will add boxed warnings to insomnia drugs, bringing it in line with other regulators, even as a study in JAMA Internal Medicine study indicates that national drug authorities often disagree more broadly over when to issue safety advisories.
Drug Safety FDA
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register